Characterisation of disseminated tumor cells in the bone marrow of breast cancer patients by the Thomsen-Friedenreich tumor antigen

Histochemistry and Cell Biology

Volumn 123, Issue 6, 2005, Pages 631-637

  Schindlbeck, Christian ^a   Jeschke, Udo ^a   Schulze, Sandra ^a   Karsten, Uwe ^b   Janni, Wolfgang ^a   Rack, Brigitte ^a   Sommer, Harald ^a   Friese, Klaus ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b MAX DELBRÜCK CENTER FOR MOLECULAR MEDICINE   (Germany)

Author keywords

Bone marrow; Breast cancer; Disseminated tumor cells; Metastasis; Minimal residual disease; MUC1; Prognosis; Therapy; Thomsen Friedenreich antigen

Indexed keywords

CARRIER PROTEIN; CYTOKERATIN; CYTOKERATIN ANTIBODY; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MUCIN 1; THOMSEN FRIEDENREICH TUMOR ANTIGEN; TUMOR ANTIGEN; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BONE MARROW; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; IMMUNOMAGNETIC SEPARATION; MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; STAINING; TUMOR CELL;

ADULT; AGED; ANTIGENS, TUMOR-ASSOCIATED, CARBOHYDRATE; BIOPSY, NEEDLE; BONE MARROW; BONE MARROW EXAMINATION; BONE MARROW NEOPLASMS; BREAST NEOPLASMS; CA-15-3 ANTIGEN; CELL LINE, TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KERATINS; MICROSCOPY, FLUORESCENCE; MIDDLE AGED; NEOPLASM STAGING;

CAPRA HIRCUS;

EID: 23744466035     PISSN: 09486143     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00418-005-0781-6     Document Type: Article

References (38)

1. Baldus SE, Zirbes TK, Hanisch FG, Kunze D, Shafizadeh ST, Nolden S, Monig SP, Schneider PM, Karsten U, Thiele J, Holscher AH, Dienes HP (2000) Thomsen-Friedenreich antigen presents as a prognostic factor in colorectal carcinoma: a clinicopathologic study of 264 patients. Cancer 88:1536-1543
2. Barr N, Taylor CR, Young T, Springer GF (1989) Are pancarcinoma T and Tn differentiation antigens? Cancer 64:834-841
3. Becker N (2001) Development of the incidence and mortality of breast cancer. Radiologie 41:337-343
4. Braun S, Hepp F, Kentenich CR, Janni W, Pantel K, Riethmuller G, Willgeroth F, Sommer HL (1999) Monoclonal antibody therapy with edrecolomab in breast cancer patients: monitoring of elimination of disseminated cytokeratin-positive tumor cells in bone marrow. Clin Cancer Res 5:3999-4004
5. Braun S, Kentenich C, Janni W, Hepp F, de Waal J, Willgeroth F, Sommer H, Pantel K (2000a) Lack of effect of adjuvant chemotherapy on the elimination of single dormant tumor cells in bone marrow of high-risk breast cancer patients. J Clin Oncol 18:80-86
6. Braun S, Pantel K, Muller P, Janni W, Hepp F, Kentenich CR, Gastroph S, Wischnik A, Dimpfl T, Kindermann G, Riethmuller G, Schlimok G (2000b) Cytokeratin-positive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer. N Engl J Med 342:525-533
7. Braun S, Schlimok G, Heumos I, Schaller G, Riethdorf L, Riethmuller G, Pantel K (2001) ErbB2 overexpression on occult metastatic cells in bone marrow predicts poor clinical outcome of stage I-III breast cancer patients. Cancer Res 61:1890-1895
8. Braun S, Vogl F, Schlimok G, Diel IJ, Coombes CR, Gerber B, Janni W, Gebauer G, Pantel K (2003) Pooled analysis of prognostic impact of occult metastatic cells (OMC) in bone marrow: 10-year survival of 3448 breast cancer patients. Proc Am Soc Clin Oncol (abstr 3402) 22:847
9. Cao Y, Stosiek P, Springer GF, Karsten U (1996) Thomsen-Friedenreich- related carbohydrate antigens in normal adult human tissues: a systematic and comparative study. Histochem Cell Biol 106:197-207
10. Fisher B, Jeong JH, Anderson S, Bryant J, Fisher ER, Wolmark N (2002) Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 347:567-575
11. Gebauer G, Fehm T, Merkle E, Beck EP, Lang N, Jager W (2001) Epithelial cells in bone marrow of breast cancer patients at time of primary surgery: clinical outcome during long-term follow-up. J Clin Oncol 19:3669-3674
12. Gerber B, Krause A, Muller H, Richter D, Reimer T, Makovitzky J, Herrnring C, Jeschke U, Kundt G, Friese K (2001) Simultaneous immunohistochemical detection of tumor cells in lymph nodes and bone marrow aspirates in breast cancer and its correlation with other prognostic factors. J Clin Oncol 19:960-971
13. Goletz S, Cao Y, Danielczyk A, Ravn P, Schoeber U, Karsten U (2003) Thomsen-Friedenreich antigen: the "hidden" tumor antigen. Adv Exp Med Biol 535:147-162
14. Hirao T, Sakamoto Y, Kamada M, Hamada S, Aono T (1993) Tn antigen, a marker of potential for metastasis of uterine cervix cancer cells. Cancer 72:154-159
15. Imai J, Ghazizadeh M, Naito Z, Asano G (2001) Immunohistochemical expression of T, Tn and sialyl-Tn antigens and clinical outcome in human breast carcinoma. Anticancer Res 21:1327-1334
16. Janni W, Gastroph S, Hepp F, Kentenich C, Rjosk D, Schindlbeck C, Dimpfl T, Sommer H, Braun S (2000) Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma. Cancer 88:2252-2259
17. Jeschke U, Richter DU, Hammer A, Briese V, Friese K, Karsten U (2002) Expression of the Thomsen-Friedenreich antigen and of its putative carrier protein mucin 1 in the human placenta and in trophoblast cells in vitro. Histochem Cell Biol 117:219-226
18. Karsten U, Butschak G, Cao Y, Goletz S, Hanisch FG (2004) A new monoclonal antibody (A78-G/A7) to the Thomsen-Friedenreich pan-tumor antigen. Hybridoma 14:37-44
19. Kasper M, Stosiek P, Typlt H, Karsten U (1987) Histological evaluation of three new monoclonal anti-cytokeratin antibodies. 1. Normal tissues. Eur J Cancer Clin Oncol 23:137-147
20. Khaldoyanidi SK, Glinsky VV, Sikora L, Glinskii AB, Mossine VV, Quinn TP, Glinsky GV, Sriramarao P (2003) MDA-MB-435 human breast carcinoma cell homo- and heterotypic adhesion under flow conditions is mediated in part by Thomsen-Friedenreich antigen-galectin-3 interactions. J Biol Chem 278:4127-4134
21. Klemi PJ, Parvinen I, Pylkkanen L, Kauhava L, Immonen-Raiha P, Rasanen O, Helenius H (2003) Significant improvement in breast cancer survival through population-based mammography screening. Breast 12:308-313
22. Landys K, Persson S, Kovarik J, Hultborn R, Holmberg E (1998) Prognostic value of bone marrow biopsy in operable breast cancer patients at the time of initial diagnosis: results of a 20-year median follow-up. Breast Cancer Res Treat 49:27-33
23. Mansi JL, Gogas H, Bliss JM, Gazet JC, Berger U, Coombes RC (1999) Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up study. Lancet 354:197-202
24. Naume B, Borgen E, Beiske K, Herstad TK, Ravnas G, Renolen A, Trachsel S, Thrane-Steen K, Funderud S, Kvalheim G (1997) Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood. J Hematother 6:103-114
25. Pantel K, Braun S (2001) Molecular determinants of occult metastatic tumor cells in bone marrow. Clin Breast Cancer 2:222-228
26. Pantel K, Schlimok G, Braun S, Kutter D, Lindemann F, Schaller G, Funke I, Izbicki JR, Riethmuller G (1993) Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells. J Natl Cancer Inst 85:1419-1424
27. Pantel K, Muller V, Auer M, Nusser N, Harbeck N, Braun S (2003) Detection and clinical implications of early systemic tumor cell dissemination in breast cancer. Clin Cancer Res 9:6326-6334
28. Price MR, Rye PD, Petrakou E, Murray A, Brady K, Imai S, Haga S, Kiyozuka Y, Schol D, Meulenbroek MF, Snijdewint FG, von Mensdorff-Pouilly S, Verstraeten RA, Kenemans P, Blockzjil A, Nilsson K, Nilsson O, Reddish M, Suresh MR, Koganty RR, Fortier S, Baronic L, Berg A, Longenecker MB, Hilgers J (1998) Summary report on the ISOBM TD-4 Workshop: analysis of 56 monoclonal antibodies against the MUC1 mucin. San Diego, Calif. 1998. Tumour Biol 19 (Suppl 1):1-20
29. van Rooijen JJ, Jeschke U, Kamerling JP, Vliegenthart JF (1998) Expression of N-linked sialyl Le(x) determinants and O-glycans in the carbohydrate moiety of human amniotic fluid transferrin during pregnancy. Glycobiology 8:1053-1064
30. Schindlbeck C, Janni W, Schaffer P, Shabani N, Schmitt M, Harbeck N, Sommer H, Braun S (2002) Tumor biology of primary breast cancer and minimal residual disease. Acta Med Austriaca 29(Suppl 59):27-31
31. Schindlbeck C, Janni W, Shabani N, Rack B, Gerber B, Schmitt M, Harbeck N, Sommer H, Braun S, Friese K (2004) Comparative analysis between the HER2 status in primary breast cancer tissue and the detection of isolated tumor cells in the bone marrow. Breast Cancer Res Treat 87:65-74
32. Schmidt-Kittler O, Ragg T, Daskalakis A, Granzow M, Ahr A, Blankenstein TJ, Kaufmann M, Diebold J, Arnholdt H, Muller P, Bischoff J, Harich D, Schlimok G, Riethmuller G, Eils R, Klein CA (2003) From latent disseminated cells to overt metastasis: genetic analysis of systemic breast cancer progression. Proc Natl Acad Sci USA 100:7737-7742
33. Sloane JP, Ormerod MG, Neville AM (1980) Potential pathological application of immunocytochemical methods to the detection of micrometastases. Cancer Res 40:3079-3082
34. Springer GF, Desai PR, Scanlon EF (1976) Blood group MN precursors as human breast carcinoma-associated antigens and "naturally" occurring human cytotoxins against them. Cancer 37:169-176
35. Springer GF, Desai PR, Murthy MS (1978) Histochemical methods for the demonstration of Thomsen-Friedenreich antigen in cell suspensions and tissue sections. Klin Wochenschr 56:761-765
36. Takanami I (1999) Expression of Thomsen-Friedenreich antigen as a marker of poor prognosis in pulmonary adenocarcinoma. Oncol Rep 6:341-344
37. Wiedswang G, Borgen E, Karesen R, Kvalheim G, Nesland JM, Qvist H, Schlichting E, Sauer T, Janbu J, Harbitz T, Naume B (2003) Detection of isolated tumor cells in bone marrow is an independent prognostic factor in breast cancer. J Clin Oncol 21:3469-3478
38. Wolf MF, Ludwig A, Fritz P, Schumacher K (1988) Increased expression of Thomsen-Friedenreich antigens during tumor progression in breast cancer patients. Tumour Biol 9:190-194